SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SSgA Active Trust - State Street SPDR S&P 500 ETF Trust

SPY is trending due to rising market anxiety over significant AI disruption impacting software and cybersecurity stocks, coupled with escalating geopolitical tensions from potential new US tariffs and military action in Iran. The community is actively discussing impending NVDA earnings and Bitcoin volatility as key factors influencing the S&P 500's uncertain path.

International Business Machines Corp. is an information technology company, which engages in the provision of integrated solutions that leverage information technology and knowledge of business processes. It operates through the following segments: Software, Consulting, Infrastructure, Financing, and Other. The Software segment combines hybrid cloud platform and software solutions to help clients become more data-driven, and to automate, secure, and modernize their environments. The Consulting segment focuses on integrating skills on strategy, experience, technology and operations by domain and industry. The Infrastructure segment offers solutions for hybrid cloud and is the foundation of the hybrid cloud stack. Infrastructure is optimized for infusing AI into mission-critical transactions and tightly integrated with IBM Software including Red Hat for accelerated hybrid cloud benefits. The Financing segment refers to the client and commercial financing, facilitating IBM clients’ acquisition of IT systems, software, and services. The company was founded by Charles Ranlett Flint and Thomas J. Watson Sr. on June 16, 1911 and is headquartered in Armonk, NY.

International Business Machines Corp.

IBM is trending following a substantial sell-off after an Anthropic blog post highlighted its Claude AI's capability to automate COBOL modernization, fueling community debate over AI's disruptive impact on legacy services versus IBM's existing AI solutions and strategic partnerships.

Vir Biotechnology, Inc. operates as a clinical-stage immunology company that focuses on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases. The firm's technology platforms include antibody, T cell, innate immunity and siRNA, which are designed to stimulate and enhance the immune system by exploiting critical observations of natural immune processes. The company was founded by Robert Taylor Nelsen, Klaus Frueh, Jay Parrish, Lawrence Corey, and Louis Picker in April 7, 2016 and is headquartered in San Francisco, CA.

Vir Biotechnology Inc

Vir Biotechnology is trending due to its global collaboration with Astellas on the VIR-5500 oncology program, which includes $335 million in upfront and near-term payments and up to $1.37 billion in potential milestones. This deal, coupled with positive Phase 1 clinical data, has the community buzzing about significant financial terms and a potential short squeeze, although some caution against a typical post-news pullback.

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Hims & Hers Health Inc - Ordinary Shares - Class A

Hims & Hers Health Inc

Hims & Hers Health Inc is actively discussed following a mixed earnings report, where an EPS beat was overshadowed by concerns over revenue growth and compressed margins, alongside escalating legal and regulatory challenges from Novo Nordisk, the FDA, DOJ, and SEC. Community sentiment is sharply divided, with some investors seeing a compelling buying opportunity due to perceived undervaluation and high short interest, while others highlight significant regulatory and legal risks predicting further declines.

Infleqtion, Inc. engages in delivering neutral atom solutions for quantum computing, networking, sensing, and security. Its products are categorized into computing, sensing, and cores. The company was founded on February 7, 2007, and is headquartered in Louisville, CO.

Infleqtion Inc. - Ordinary Shares - Class A

Infleqtion Inc.

Quantum technology firm Infleqtion (INFQ) is a hot topic following its public listing and upcoming NYSE bell ringing, with investors debating its long-term potential as a leader in quantum computing and sensing, highlighted by strategic defense and NASA contracts and significant institutional investment, while navigating typical post-SPAC volatility.

Unity Software, Inc. engages in the developing video gaming software. It also provides software solutions to create, run and monetize interactive, real-time two-dimensional and three-dimensional content for mobile phones, tablets, consoles, and augmented and virtual reality devices. Its platform is used by developers, artists, and designers to build content for gaming, film, retail, automotive, architecture, engineering, and construction industries. The company was founded by Joachim Ante and David Helgason in 2004 and is headquartered in San Francisco, CA.

Unity Software Inc

Unity Software is trending due to significant market fears that AI, specifically new tools like Google's Project Genie, poses an existential threat to its game engine business, despite a recent Q4 earnings beat and ongoing internal AI development. The community is sharply divided, with some anticipating further declines while others believe the sell-off is overblown and see Unity's robust ecosystem and upcoming AI features as a strong counter to the disruption narrative.

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.

Novo Nordisk - ADR

Novo Nordisk A/S

Novo Nordisk shares are sharply lower after its next-generation obesity drug, CagriSema, demonstrated less weight loss than Eli Lilly's rival in a head-to-head trial, sparking community debate over whether the efficacy difference justifies the steep sell-off. Many investors are viewing the decline as a potential buying opportunity, citing the company's strong fundamentals and the positive traction of its oral Wegovy pill in a rapidly expanding market.

Pinterest, Inc. engages in the operation of a pinboard-style photo-sharing website. It allows users to create and manage theme-based image collections such as events, interests, and hobbies. The company was founded by Benjamin Silbermann, Paul C. Sciarra, and Evan Sharp in October 2008 and is headquartered in San Francisco, CA.

Pinterest Inc - Ordinary Shares - Class A

Pinterest Inc

Pinterest is trending following a recent revenue miss and weak guidance, which its CEO attributed to tariff impacts on major retail advertisers, leading to a significant stock decline and multiple analyst downgrades. Amidst calls for management changes, the community is actively debating whether the company is deeply oversold and ripe for a potential acquisition given its large user base and strong balance sheet.

IonQ, Inc. develops and manufactures quantum computers. The firm specializes in quantum computing and quantum information processing. The company was founded by Christopher Monroe and Jung Sang Kim in 2015 and is headquartered in College Park, MD.

IonQ Inc

IonQ is highly discussed following its selection for the Missile Defense Agency's SHIELD contract, a significant development for its quantum technology, yet a short report alleging financial irregularities has sparked a polarized debate, with supporters pointing to recent institutional investments and calling for a short squeeze.

Mastercard, Inc. is a technology company, which engages in the provision of payment solutions for the development and implementation of credit, debit, prepaid, commercial, and payment programs through its brands including Mastercard, Maestro, and Cirrus. It also offers cyber and intelligence solutions. The company was founded in November 1966 and is headquartered in Purchase, NY.

Mastercard Incorporated - Ordinary Shares - Class A

Mastercard Inc

Mastercard is experiencing an "AI scare trade" sell-off following a Citrini Research report suggesting AI agents could disrupt its core interchange revenue model, sparking widespread community debate. While some fear a paradigm shift for legacy finance, others are actively buying the dip, dismissing the threat as overblown given Mastercard's own AI integration efforts, strong earnings, and recent share repurchase program.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Citius Pharmaceuticals Q1 Earnings Report: What Investors Need to Know

Citius Pharmaceuticals, Inc. Announces First Reported Revenue Following Successful Launch of LYMPHIR

Citius Pharmaceuticals, Inc. Announces First Reported Revenue Following Successful Launch of LYMPHIR Citius Pharmaceuticals, Inc. Announces First Reported Revenue Following Successful Launch of...

Citius Oncology, Inc. Announces First Reported Revenue Following Successful Launch of LYMPHIR

Citius Oncology, Inc. Announces First Reported Revenue Following Successful Launch of LYMPHIR Citius Oncology, Inc. Announces First Reported Revenue Following Successful Launch of LYMPHIR PR Newswire...

Citius Oncology Expands International Distribution of LYMPHIR to European Union Through Exclusive Agreement with Uniphar

Citius Oncology Expands International Distribution of LYMPHIR to European Union Through Exclusive Agreement with Uniphar Citius Oncology Expands International Distribution of LYMPHIR to European...

Citius Pharmaceuticals (CTXR) Surges 22% After Hours Here's Why

Citius Pharmaceuticals shares jumped 22.12% after hours following the commercial launch of its LYMPHIR therapy and a fiscal 2025 business update.read more...

Citius Pharmaceuticals Inc. Full Year Loss Decreases

(RTTNews) - Citius Pharmaceuticals Inc. (CTXR.OB) released Loss for full year of -$37.43 million...

Citius Oncology, Inc. Reports Fiscal Year 2025 Financial Results and Provides Business Update

Citius Oncology, Inc. Reports Fiscal Year 2025 Financial Results and Provides Business Update Citius Oncology, Inc. Reports Fiscal Year 2025 Financial Results and Provides Business Update PR Newswire...

Citius Pharmaceuticals, Inc. Reports Fiscal Year 2025 Financial Results and Provides Business Update

Citius Pharmaceuticals, Inc. Reports Fiscal Year 2025 Financial Results and Provides Business Update Citius Pharmaceuticals, Inc. Reports Fiscal Year 2025 Financial Results and Provides Business...

Citius Oncology Announces Closing of $18 Million Concurrent Registered Direct Offering and Private Placement Priced At-The-Market Under Nasdaq Rules

Citius Oncology Announces Closing of $18 Million Concurrent Registered Direct Offering and Private Placement Priced At-The-Market Under Nasdaq Rules Citius Oncology Announces Closing of $18 Million...

Citius Oncology Announces $18 Million Concurrent Registered Direct Offering and Private Placement Priced At-The-Market Under Nasdaq Rules

Citius Oncology Announces $18 Million Concurrent Registered Direct Offering and Private Placement Priced At-The-Market Under Nasdaq Rules Citius Oncology Announces $18 Million Concurrent Registered...

Citius Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and commercialization of critical care products, with a focus on oncology, anti-infectives in adjunct cancer care, prescription products, and stem cell therapy. Its products include I/ONTAK, Mino-Lok, Halo-Lido, Mino-Wrap, and Novecite. The company was founded by Ralph Montrone, Leonard Mazur, Myron Holubiak on January 23, 2007 and is headquartered in Cranford, NJ.

CTXR
Citius Pharmaceuticals Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest CTXR News

CTXRCitius Pharmaceuticals Inc